April 7 (Reuters) - Lexeo Therapeutics Inc LXEO.O:
LEXEO THERAPEUTICS ANNOUNCES POSITIVE INTERIM PHASE 1/2 DATA FOR LX2006 IN FRIEDREICH ATAXIA CARDIOMYOPATHY SUPPORTING ADVANCEMENT TO REGISTRATIONAL STUDY
LEXEO THERAPEUTICS INC: LX2006 GENERALLY WELL TOLERATED WITH NO SIGNS OF COMPLEMENT ACTIVATION OR OTHER IMMUNOGENICITY TO DATE
LEXEO THERAPEUTICS : PARTICIPANTS WITH ABNORMAL LEFT VENTRICULAR MASS INDEX AT BASELINE ACHIEVED 25% MEAN REDUCTION IN LVMI BY 12 MONTHS OR SOONER
LEXEO THERAPEUTICS : CLINICALLY MEANINGFUL IMPROVEMENTS IN MAJORITY OF PARTICIPANTS ACROSS CARDIAC BIOMARKERS & FUNCTIONAL MEASURES
Source text: ID:nGNX4F00MX
Further company coverage: LXEO.O
(((( Reuters.briefs@thomsonreuters.com ;));))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.